

Ovarian cancer population screening and mortality after
Collaborative Trial of Ovarian Cancer Screening (UKCTOC
trial

Lancet, The

397, 2182-2193

DOI: [10.1016/s0140-6736\(21\)00731-5](https://doi.org/10.1016/s0140-6736(21)00731-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Screening for ovarian cancer is ruled out after trial found it did not reduce deaths. <i>BMJ, The</i> , 2021, 373, n1223.	6.0	2
3	Could Ovarian Cancer Prediction Models Improve the Triage of Symptomatic Women in Primary Care? A Modelling Study Using Routinely Collected Data. <i>Cancers</i> , 2021, 13, 2886.	3.7	1
4	Give to Fryback what is Fryback's, and to new PET technologies what is new PET technologies's. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2676-2677.	6.4	1
5	General population screening for ovarian cancer. <i>Lancet, The</i> , 2021, 397, 2128-2130.	13.7	17
6	Epidemiological trends of women's cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study. <i>Biomarker Research</i> , 2021, 9, 55.	6.8	67
7	Future Screening Prospects for Ovarian Cancer. <i>Cancers</i> , 2021, 13, 3840.	3.7	21
8	Alcimedex for June/July edition. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2021, 81, 102218.	1.0	0
10	Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Consortium. <i>Gastroenterology</i> , 2021, 161, 1751-1757.	1.3	20
11	Ovarian-Cancer-Associated Extracellular Vesicles: Microenvironmental Regulation and Potential Clinical Applications. <i>Cells</i> , 2021, 10, 2272.	4.1	17
12	Plasma exosome-derived fragile-site associated tumor suppressor is a powerful predictor of prognosis in patients with ovarian cancer. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, , .	1.0	3
13	Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors. <i>Cancer Treatment Reviews</i> , 2021, 101, 102298.	7.7	11
14	Health screening needs independent regular re-evaluation. <i>BMJ, The</i> , 2021, 374, n2049.	6.0	7
15	Oncoprophylaxis in gynecology considering the analysis of international experience. <i>Problems and solutions. Russian Journal of Human Reproduction</i> , 2021, 27, 70.	0.3	2
16	Platelet RNA Signature Enables Early and Accurate Detection of Ovarian Cancer: An Intercontinental, Biomarker Identification Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
17	Gynecological Cancer Prevention of the Modern Era. <i>Journal of the Nihon University Medical Association</i> , 2021, 80, 167-171.	0.0	0
18	Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, .	2.3	22
19	Circulating Exosomal miRNAs as Biomarkers in Epithelial Ovarian Cancer. <i>Biomedicines</i> , 2021, 9, 1433.	3.2	13
20	Next steps in the early detection of ovarian cancer. <i>Communications Medicine</i> , 2021, 1, .	4.2	16

#	ARTICLE	IF	CITATIONS
21	The Development of Nanoparticles for the Detection and Imaging of Ovarian Cancers. <i>Biomedicines</i> , 2021, 9, 1554.	3.2	2
22	A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen. <i>Gynecologic Oncology</i> , 2021, , .	1.4	1
23	Conservative Management of Asymptomatic Adnexal Masses Classified as Benign by the IOTA ADNEX Model: A Prospective Multicenter Portuguese Study. <i>Diagnostics</i> , 2021, 11, 1992.	2.6	1
24	Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead. <i>Journal of Hepatology</i> , 2022, 76, 981-982.	3.7	5
25	Recommendations for diagnosing STIC: a systematic review and meta-analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 725-737.	2.8	15
26	Significance of Pelvic Fluid Observed during Ovarian Cancer Screening with Transvaginal Sonogram. <i>Diagnostics</i> , 2022, 12, 144.	2.6	1
27	Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer. <i>BMC Cancer</i> , 2022, 22, 6.	2.6	14
28	Ovarian cancer and KiSS-1 gene expression: A consideration of the use of Kisspeptin plus Kisspeptin aptamers in diagnostics and therapy. <i>European Journal of Pharmacology</i> , 2022, 917, 174752.	3.5	2
29	Oncoprophylaxis in gynecology considering the analysis of international experience. Problems and solutions. <i>Russian Journal of Human Reproduction</i> , 2021, 27, 70.	0.3	1
30	Predicting Ovarian-Cancer Burden in Catalonia by 2030: An Age-Period Cohort Modelling. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1404.	2.6	4
31	High-grade ovarian cancer associated H/ACA snoRNAs promote cancer cell proliferation and survival. <i>NAR Cancer</i> , 2022, 4, zcab050.	3.1	10
32	Special Issue "Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer". <i>Cancers</i> , 2022, 14, 319.	3.7	2
33	The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 799171.	4.8	6
34	Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer. <i>British Journal of Cancer</i> , 2022, 126, 1301-1309.	6.4	22
35	STop OVarian CAncer (STOPOVCA) young: Protocol for a multicenter follow-up study to determine the long-term effects of opportunistic salpingectomy on age at menopause. <i>Maturitas</i> , 2022, 159, 62-68.	2.4	5
36	"Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management. <i>Oncologist</i> , 2022, 27, e393-e401.	3.7	5
37	Up-regulation of MTHFD2 is associated with clinicopathological characteristics and poor survival in ovarian cancer, possibly by regulating MOB1A signaling. <i>Journal of Ovarian Research</i> , 2022, 15, 23.	3.0	9
38	Overexpression of Stathmin 1 Predicts Poor Prognosis and Promotes Cancer Cell Proliferation and Migration in Ovarian Cancer. <i>Disease Markers</i> , 2022, 2022, 1-15.	1.3	5

#	ARTICLE	IF	CITATIONS
39	Universal Germline Genetic Testing in Epithelial Ovarian Cancer: Promises and challenges. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.2	0
40	Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention. <i>JAMA Network Open</i> , 2022, 5, e2147343.	5.9	41
41	Major clinical research advances in gynecologic cancer in 2021. <i>Journal of Gynecologic Oncology</i> , 2022, 33, e43.	2.2	19
42	The peri-menopause is a critical period for women. <i>Obstetrics & Gynecology International Journal</i> , 2022, 13, 19-24.	0.1	0
43	Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. <i>Cells</i> , 2022, 11, 650.	4.1	34
45	Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. <i>The Cochrane Library</i> , 2022, 2022, CD007929.	2.8	22
46	Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 1879-1891.	1.6	25
47	Incidence of ovarian cancer after bilateral salpingo-oophorectomy in women with histologically proven endometriosis. <i>Fertility and Sterility</i> , 2022, 117, 938-945.	1.0	3
48	Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1757.	3.7	12
49	Raman spectroscopic study of benign and malignant ovarian tissues. <i>Laser Physics</i> , 2022, 32, 035601.	1.2	2
50	A qualitative exploration of women's perspectives and acceptability of including new cancer awareness information in all-€clear breast or cervical screening results. <i>European Journal of Cancer Care</i> , 2022, , .	1.5	1
51	Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic study. <i>The Lancet Digital Health</i> , 2022, 4, e179-e187.	12.3	37
52	Neutrophilâ€“Lymphocyte and Plateletâ€“Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors. <i>Journal of Clinical Medicine</i> , 2022, 11, 1355.	2.4	9
53	N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease. <i>BMC Cancer</i> , 2022, 22, 334.	2.6	7
54	Detection of ovarian cancer via the spectral fingerprinting of quantum-defect-modified carbon nanotubes in serum by machine learning. <i>Nature Biomedical Engineering</i> , 2022, 6, 267-275.	22.5	65
55	Early detection of cancer. <i>Science</i> , 2022, 375, eaay9040.	12.6	291
56	mPEG-PDLLA Micelles Potentiate Docetaxel for Intraperitoneal Chemotherapy in Ovarian Cancer Peritoneal Metastasis. <i>Frontiers in Pharmacology</i> , 2022, 13, 861938.	3.5	4
57	Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2022, 86, 207-223.	9.6	35

#	ARTICLE	IF	CITATIONS
58	Current Research Progress of the Role of LncRNA LEF1-AS1 in a Variety of Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 750084.	3.7	3
59	Cancer therapies: Caveats, concerns, and momentum. , 2022, , 401-430.		0
60	The future of early cancer detection. <i>Nature Medicine</i> , 2022, 28, 666-677.	30.7	92
61	Screening and risk reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 646-655.	2.5	4
62	Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews. <i>Diagnostics</i> , 2022, 12, 1028.	2.6	3
63	A Translational Model to Improve Early Detection of Epithelial Ovarian Cancers. <i>Frontiers in Oncology</i> , 2022, 12, 786154.	2.8	1
64	Multicancer Early Detection Technologies: A Review Informed by Past Cancer Screening Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1139-1145.	2.5	7
65	Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis. <i>EBioMedicine</i> , 2022, 79, 104001.	6.1	54
66	The highly effective therapy of ovarian cancer by Bismuth-doped oxygen-deficient BaTiO ₃ with enhanced sono-piezocatalytic effects. <i>Chemical Engineering Journal</i> , 2022, 442, 136380.	12.7	27
68	Double trouble: whole genome doubling distinguishes early from late ovarian cancer. <i>Clinical Cancer Research</i> , 2022, , .	7.0	1
69	Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1298-1304.	2.5	14
70	Injectable three-dimensional tumor microenvironments to study mechanobiology in ovarian cancer. <i>Acta Biomaterialia</i> , 2022, 146, 222-234.	8.3	3
71	miR-600 promotes ovarian cancer cells stemness, proliferation and metastasis via targeting KLF9. <i>Journal of Ovarian Research</i> , 2022, 15, 52.	3.0	10
72	Applications of Proteomics in Ovarian Cancer: Dawn of a New Era. <i>Proteomes</i> , 2022, 10, 16.	3.5	66
73	Application of artificial intelligence in the diagnosis and prognostic prediction of ovarian cancer. <i>Computers in Biology and Medicine</i> , 2022, 146, 105608.	7.0	8
74	Opportunistic salpingectomy between 2011 and 2016: a descriptive analysis. <i>CMAJ Open</i> , 2022, 10, E466-E475.	2.4	5
75	Diagnostic Value of Two-Dimensional Transvaginal Ultrasound Combined with Contrast-Enhanced Ultrasound in Ovarian Cancer. <i>Frontiers in Surgery</i> , 2022, 9, .	1.4	1
76	Non-Coding RNAs Delivery by Small Extracellular Vesicles and Their Applications in Ovarian Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, .	4.1	2

#	ARTICLE	IF	CITATIONS
77	Initial evaluation in the climacteric. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2022, 44, 548-556.	0.8	0
78	Ovarian cancer in primary care. <i>InnovAiT</i> , 0, , 175573802211068.	0.0	0
79	MRI in liver cirrhosis. , 2022, 1, 23-41.		0
80	Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer. <i>Cancers</i> , 2022, 14, 3077.	3.7	4
81	Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	18
82	The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2022, 151, 1626-1639.	5.1	8
83	Etiopathogenesis of ovarian cancer. An inflamm-aging entity?. <i>Gynecologic Oncology Reports</i> , 2022, 42, 101018.	0.6	7
84	Targeted peptide-modified oxidized mesoporous carbon nanospheres for chemo-thermo combined therapy of ovarian cancer <i>in vitro</i> . <i>Drug Delivery</i> , 2022, 29, 1951-1958.	5.7	5
85	Detecting ovarian cancer in primary care: can we do better?. <i>British Journal of General Practice</i> , 2022, 72, 312-313.	1.4	1
86	Novel LncRNA ZFH4-AS1 as a Potential Prognostic Biomarker That Affects the Immune Microenvironment in Ovarian Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	7
87	Management of the Adnexal Mass: Considerations for the Family Medicine Physician. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	5
88	Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify. <i>British Journal of Cancer</i> , 2022, 127, 1263-1269.	6.4	11
89	The global burden and associated factors of ovarian cancer in 1990â€“2019: findings from the Global Burden of Disease Study 2019. <i>BMC Public Health</i> , 2022, 22, .	2.9	11
90	Antibacterial and anticancer potential of mycosynthesized titanium dioxide (TiO2) nanoparticles using <i>Hypsizyugus ulmarius</i> . <i>Biomass Conversion and Biorefinery</i> , 0, , .	4.6	5
91	Advances on Prevention and Screening of Gynecologic Tumors: Are We Stepping Forward?. <i>Healthcare (Switzerland)</i> , 2022, 10, 1605.	2.0	34
92	Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer. <i>Genes and Diseases</i> , 2023, 10, 1005-1018.	3.4	4
94	Screening for Ovarian Cancer in the General Population: State of Art and Perspectives of Clinical Research. <i>Anticancer Research</i> , 2022, 42, 4207-4216.	1.1	2
95	Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer. <i>EBioMedicine</i> , 2022, 83, 104222.	6.1	17

#	ARTICLE	IF	CITATIONS
96	The effect of opportunistic salpingectomy for primary prevention of ovarian cancer on ovarian reserve: a systematic review and meta-analysis. <i>Maturitas</i> , 2022, 166, 21-34.	2.4	4
97	The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9981.	4.1	2
98	Risk stratification and early detection biomarkers for precision HCC screening. <i>Hepatology</i> , 2023, 78, 319-362.	7.3	13
99	Anti-Cancer Activity of Cannabis sativa Phytocannabinoids: Molecular Mechanisms and Potential in the Fight against Ovarian Cancer and Stem Cells. <i>Cancers</i> , 2022, 14, 4299.	3.7	8
100	Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	4
101	Post-transcriptional gene regulation in solid tumors. , 2022, , 119-148.		0
102	Early diagnosis of symptomatic ovarian cancer in primary care in the UK: opportunities and challenges. <i>Primary Health Care Research and Development</i> , 2022, 23, .	1.2	3
103	Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
104	Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome. <i>Cancers</i> , 2022, 14, 4717.	3.7	1
105	Blood-based DNA methylation profiling for the detection of ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 167, 295-305.	1.4	4
106	Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers. <i>Cancers</i> , 2022, 14, 4724.	3.7	0
107	Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12057.	2.6	17
108	Ovarian cancer risk management in BRCA-mutation carriers: A comparison of six international and national guidelines. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 278, 166-171.	1.1	5
109	Introduction: Trends, Puzzles, and Hopes for the Future of Healthcare. <i>Future of Business and Finance</i> , 2022, , 1-24.	0.4	1
110	Proteomic signature for detection of high-grade ovarian cancer in germline <i>BRCA</i> mutation carriers. <i>International Journal of Cancer</i> , 0, , .	5.1	1
111	From the patient to the population: Use of genomics for population screening. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	6
112	Molecular Biomarkers for the Early Detection of Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12041.	4.1	42
113	Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12067.	4.1	15

#	ARTICLE	IF	CITATIONS
114	Pathways to diagnosis of endometrial and ovarian cancer in the 45 and Up Study cohort. <i>Cancer Causes and Control</i> , 0, , .	1.8	0
115	Metabolic reprogramming of the tumor immune microenvironment in ovarian cancer: A novel orientation for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
116	Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial. <i>Cancers</i> , 2022, 14, 4818.	3.7	42
118	Diagnostics of Ovarian Tumors in Postmenopausal Patients. <i>Diagnostics</i> , 2022, 12, 2619.	2.6	1
119	The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in <i>BRCA1</i> and <i>BRCA2</i> . <i>Journal of Medical Genetics</i> , 2023, 60, 440-449.	3.2	8
120	Single-molecule array assay reveals the prognostic impact of plasma LRIG1 in ovarian carcinoma. <i>Acta Oncologica</i> , 2022, 61, 1425-1433.	1.8	0
121	Early-Stage epithelial ovarian cancer: Predictors of survival. <i>Gynecologic Oncology Reports</i> , 2022, 44, 101083.	0.6	1
122	Meta-analyses reveal serum or plasma Interleukin-6 as a biomarker for malignant ovarian neoplasia. <i>Cytokine</i> , 2023, 161, 156073.	3.2	1
123	Cistoadenoma Mucinoso gigante de ovario asociado a adenomucinositis peritoneal diseminada.. <i>Medicinas UTA</i> , 2022, 6, 61-68.	0.1	0
124	Phytocannabinoid Compositions from Cannabis Act Synergistically with PARP1 Inhibitor against Ovarian Cancer Cells In Vitro and Affect the Wnt Signaling Pathway. <i>Molecules</i> , 2022, 27, 7523.	3.8	7
126	Pathways to ovarian cancer diagnosis: a qualitative study. <i>BMC Women's Health</i> , 2022, 22, .	2.0	5
127	Fallopian tube secreted protein affects ovarian metabolites in high grade serous ovarian cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	2
128	Diagnostic accuracy of mutational analysis along the Müllerian tract to detect ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1568-1575.	2.5	2
129	Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. <i>British Journal of Cancer</i> , 2023, 128, 342-353.	6.4	17
130	A combined clinical and genetic model for predicting risk of ovarian cancer. <i>European Journal of Cancer Prevention</i> , 2023, 32, 57-64.	1.3	0
132	Assessing new screening tests. <i>Canadian Family Physician</i> , 2022, 68, 815-822.	0.4	0
133	A Coculture Based, 3D Bioprinted Ovarian Tumor Model Combining Cancer Cells and Cancer Associated Fibroblasts. <i>Macromolecular Bioscience</i> , 2023, 23, .	4.1	5
134	Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq. <i>Journal of Ovarian Research</i> , 2022, 15, .	3.0	7

#	ARTICLE	IF	CITATIONS
135	Women's experiences along the ovarian cancer diagnostic pathway in Catalonia: A qualitative study. <i>Health Expectations</i> , 2023, 26, 476-487.	2.6	4
136	UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: <i>RAD51C</i> , <i>RAD51D</i> , <i>BRIP1</i> and <i>PALB2</i> . <i>Journal of Medical Genetics</i> , 2023, 60, 417-429.	3.2	8
137	À%valuer les nouveaux tests de d'À©pistage. <i>Canadian Family Physician</i> , 2022, 68, e310-e317.	0.4	0
138	Evaluation of the Diagnostic Potential of Circulating MicroRNAs <i>miR-1</i> and <i>miR-21</i> in Patients With Ovarian Cancer. <i>Anticancer Research</i> , 2022, 42, 5839-5845.	1.1	2
139	The role of interferons in ovarian cancer progression: Hinderer or promoter?. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
140	tRNA-derived small RNA 3'â€²U-trFValCAC promotes tumour migration and early progression in ovarian cancer. <i>European Journal of Cancer</i> , 2023, 180, 134-145.	2.8	4
141	Repurposing organic semiconducting nanomaterials to accelerate clinical translation of NIR-II fluorescence imaging. <i>Nano Research</i> , 2023, 16, 5140-5154.	10.4	7
142	miR-219-5p attenuates cisplatin resistance of ovarian cancer by inactivating <i>Wnt/Î²-catenin</i> signaling and autophagy via targeting <i>HMGA2</i> . <i>Cancer Gene Therapy</i> , 2023, 30, 596-607.	4.6	3
143	Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review. <i>Cancers</i> , 2022, 14, 6117.	3.7	3
144	Study design considerations for trials to evaluate multicancer early detection assays for clinical utility. <i>Journal of the National Cancer Institute</i> , 2023, 115, 250-257.	6.3	11
146	The importance of long-term follow up of participants in clinical trials. <i>British Journal of Cancer</i> , 2023, 128, 432-438.	6.4	6
147	Protein Glycosylation as Biomarkers in Gynecologic Cancers. <i>Diagnostics</i> , 2022, 12, 3177.	2.6	1
149	Impact of Hormone Replacement Therapy on the Overall Survival and Progression Free Survival of Ovarian Cancer Patients: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2023, 15, 356.	3.7	5
150	LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. <i>Scientific Reports</i> , 2023, 13, .	3.3	5
151	Imaging Recommendations for Diagnosis, Staging, and Management of Ovarian and Fallopian Tube Cancers. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.2	0
152	PCDH17 gene promoter methylation status in a cohort of Egyptian women with epithelial ovarian cancer. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
153	Validation of a deep neural network-based algorithm supporting clinical management of adnexal mass. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	1
156	A questionnaire-based survey on the diagnostic and therapeutic approaches for patients with STIC in Germany. <i>Archives of Gynecology and Obstetrics</i> , 0, , .	1.7	0

#	ARTICLE	IF	CITATIONS
157	Association Between Purchase of Over-the-Counter Medications and Ovarian Cancer Diagnosis in the Cancer Loyalty Card Study (CLOCS): Observational Case-Control Study. <i>JMIR Public Health and Surveillance</i> , 0, 9, e41762.	2.6	10
158	Therapeutic effect of haploidentical peripheral blood stem cell treatment on relapsed/refractory ovarian cancer. <i>Bulletin Du Cancer</i> , 2023, 110, 285-292.	1.6	1
159	Performance of IOTA Simple Rules Risks, ADNEX Model, Subjective Assessment Compared to CA125 and HE4 with ROMA Algorithm in Discriminating between Benign, Borderline and Stage I Malignant Adnexal Lesions. <i>Diagnostics</i> , 2023, 13, 885.	2.6	7
160	A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer. <i>Biomedicine and Pharmacotherapy</i> , 2023, 160, 114304.	5.6	7
161	Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2023, 229, 388-409.e4.	1.3	4
162	Quantification of overdiagnosis in randomised trials of cancer screening: an overview and re-analysis of systematic reviews. <i>Cancer Epidemiology</i> , 2023, 84, 102352.	1.9	2
164	Oncogenic SIRT7 inhibits GATA4 transcriptional activity and activates the Wnt signaling pathway in ovarian cancer. <i>Gynecologic Oncology</i> , 2023, 171, 39-48.	1.4	4
166	Recent Advances in Gynaecological Oncology. , 2022, , 475-494.		0
167	Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review. <i>Cancers</i> , 2023, 15, 711.	3.7	2
168	Niosomes nanoparticles as a novel approach in drug delivery enhances anticancer properties of chrysin in human ovarian carcinoma cells (SKOV3): an in vitro study. , 2023, 40, .		3
169	Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis. <i>Journal of Obstetrics and Gynaecology</i> , 2023, 43, .	0.9	4
171	An Assessment of Serum Selenium Concentration in Women with Ovarian Cancer. <i>Nutrients</i> , 2023, 15, 850.	4.1	2
172	Prophylactic Radical Fimbriectomy with Delayed Oophorectomy in Women with a High Risk of Developing an Ovarian Carcinoma: Results of a Prospective National Pilot Study. <i>Cancers</i> , 2023, 15, 1141.	3.7	6
173	N6-methyladenosine methylation regulator FTO promotes oxidative stress and induces cell apoptosis in ovarian cancer. <i>Epigenomics</i> , 2022, 14, 1509-1522.	2.1	4
174	The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis. <i>Clinical Therapeutics</i> , 2023, 45, 278-289.	2.5	5
175	Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies. <i>Annals of Oncology</i> , 2023, 34, 486-495.	1.2	11
176	Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers. <i>World Journal of Oncology</i> , 2023, 14, 4-14.	1.5	11
177	Impact of lower co-payments on risk-reducing salpingo-oophorectomy and BRCA testing in Japan. <i>Archives of Public Health</i> , 2023, 81, .	2.4	0

#	ARTICLE	IF	CITATIONS
178	IDEA group consensus statement on medical management of adult gender incongruent individuals seeking gender affirmation as male. <i>Indian Journal of Endocrinology and Metabolism</i> , 2023, 27, 3.	0.4	0
179	MUM1L1 as a Tumor Suppressor and Potential Biomarker in Ovarian Cancer: Evidence from Bioinformatics Analysis and Basic Experiments. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2023, 26, .	1.1	0
180	Prevention over screening for ovarian cancer in patients with high-risk germline mutations: Misinterpreting the findings of ALDO. <i>Gynecologic Oncology Reports</i> , 2023, 46, 101157.	0.6	0
181	A Dual Biomarker TK1 Protein and CA125 or HE4-Based Algorithm as a Better Diagnostic Tool than ROMA Index in Early Detection of Ovarian Cancer. <i>Cancers</i> , 2023, 15, 1593.	3.7	4
182	Association between Preoperative 18-FDG PET-CT SUVmax and Next-Generation Sequencing Results in Postoperative Ovarian Malignant Tissue in Patients with Advanced Ovarian Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 2287.	2.4	0
183	Prediction of Surgical Outcome in Advanced Ovarian Cancer by Imaging and Laparoscopy: A Narrative Review. <i>Cancers</i> , 2023, 15, 1904.	3.7	5
184	Bufalin-loaded vitamin E succinate-grafted chitosan oligosaccharide/RGD-conjugated TPGS mixed micelles inhibit intraperitoneal metastasis of ovarian cancer. <i>Cancer Nanotechnology</i> , 2023, 14, .	3.7	1
185	Alcohol intake and the risk of epithelial ovarian cancer. <i>Cancer Causes and Control</i> , 0, , .	1.8	1
186	Primary prevention of ovarian cancer by salpingectomy: that's one small step for a surgeon, one giant leap for patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
187	Real-world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non-interventional study in China. <i>Cancer Communications</i> , 0, , .	9.2	1
188	A practical approach to managing post-menopausal women with ovarian cysts. <i>Obstetrics, Gynaecology and Reproductive Medicine</i> , 2023, , .	0.3	0
189	Clinical Efficacy and Safety of Tumor Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Ovarian Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2023, 2023, 1-8.	1.2	1
190	Health services costs for ovarian cancer in Australia: Estimates from the 45 and Up Study. <i>PLoS ONE</i> , 2023, 18, e0282851.	2.5	0
191	Ultrasound-identified ovarian cysts: a guide to interpretation, management, and follow-up. <i>Menopause</i> , 0, Publish Ahead of Print, .	2.0	0
192	Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial. <i>Health Technology Assessment</i> , 0, , 1-81.	2.8	3
193	The role of fibroblast growth factor 18 in cancers: functions and signaling pathways. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
194	Patient-derived organoids in ovarian cancer: Current research and its clinical relevance. <i>Biochemical Pharmacology</i> , 2023, 213, 115589.	4.4	2
196	Tumor-Infiltrating Lymphocytes (TILs) and Gynecological Cancers. , 2023, , .		1

#	ARTICLE	IF	CITATIONS
197	SPON1 is an independent prognostic biomarker for ovarian cancer. <i>Journal of Ovarian Research</i> , 2023, 16, .	3.0	1
198	Sexually Transmitted Infections and Risk of Epithelial Ovarian Cancer: Results From the Finnish Maternity Cohort. <i>Journal of Infectious Diseases</i> , 0, , .	4.0	0
199	Identification of metabolic biomarkers for diagnosis of epithelial ovarian cancer using internal extraction electrospray ionization mass spectrometry (iEESI-MS). <i>Cancer Biomarkers</i> , 2023, 37, 67-84.	1.7	1
201	Leucyl and Cystinyl Aminopeptidase as a Prognostic-Related Biomarker in OV Correlating with Immune Infiltrates. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 16, 551-568.	0.7	0
204	â€œWhat consumers and manufacturers need to know about non-invasive diagnostic tests for endometriosis. , 2023, 2, 100031.		3
205	An Integrated Approach to Protein Discovery and Detection From Complex Biofluids. <i>Molecular and Cellular Proteomics</i> , 2023, 22, 100590.	3.8	3
206	Adherence to risk-reducing salpingo-oophorectomy guidelines among gynecologic oncologists compared to general gynecologists. <i>American Journal of Obstetrics and Gynecology</i> , 2023, 229, 280.e1-280.e8.	1.3	0
207	Cancer Loyalty Card Study (CLOCS): feasibility outcomes for an observational caseâ€“control study focusing on the patient interval in ovarian cancer. <i>BMJ Open</i> , 2023, 13, e066022.	1.9	1
208	Diagnostic performance of IOTA SR and O-RADS combined with CA125, HE4, and risk of malignancy algorithm to distinguish benign and malignant adnexal masses. <i>European Journal of Radiology</i> , 2023, 165, 110926.	2.6	0
209	Deceptive measures of progress in the NHS long-term plan for cancer: case-based vs. population-based measures. <i>British Journal of Cancer</i> , 2023, 129, 3-7.	6.4	1
210	OCRA encourages fallopian tube removal for women undergoing pelvic surgeries for benign conditions. <i>Cancer</i> , 2023, 129, 2116-2116.	4.1	0
211	Maveropemut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial. <i>Clinical Cancer Research</i> , 2023, 29, 2808-2815.	7.0	2
212	Prevalence of Germline Pathogenic BRCA mutations in women with High grade Serous ovarian cancers. <i>Indian Journal of Gynecologic Oncology</i> , 2023, 21, .	0.3	0
213	Dying To Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2023, 32, 1003-1010.	2.5	2
214	Use of Period Analysis to Timely Assess Five-Year Relative Survival for Patients with Ovarian Cancer from Taizhou, Eastern China. <i>Journal of Clinical Medicine</i> , 2023, 12, 3480.	2.4	0
216	Profiling the metabolome of uterine fluid for early detection of ovarian cancer. <i>Cell Reports Medicine</i> , 2023, 4, 101061.	6.5	1
217	Salpingectomy in Ovarian Cancer Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 2015.	7.4	6
218	CA125 Levels in BRCA mutation carriers â€“ a retrospective single center cohort study. <i>BMC Cancer</i> , 2023, 23, .	2.6	2

#	ARTICLE	IF	CITATIONS
219	Early diagnostics of aggressive cancers: alliance of physicians, technologies and artificial intelligence. <i>Diagnostic Radiology and Radiotherapy</i> , 2023, 14, 7-14.	0.2	0
220	Identifying high-grade serous ovarian carcinoma-specific extracellular vesicles by polyketone-coated nanowires. <i>Science Advances</i> , 2023, 9, .	10.3	5
221	Deprivation and segregation in ovarian cancer survival among African American women: a mediation analysis. <i>Annals of Epidemiology</i> , 2023, 86, 57-64.	1.9	1
222	Inaugurating High-Throughput Profiling of Extracellular Vesicles for Earlier Ovarian Cancer Detection. <i>Advanced Science</i> , 2023, 10, .	11.2	4
223	Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2023, 32, 1402-1410.	2.5	1
224	Noninvasive early differential diagnosis and progression monitoring of ovarian cancer using the copy number alterations of plasma cell-free DNA. <i>Translational Research</i> , 2023, , .	5.0	1
225	Blood Plasma Small Non-Coding RNAs as Diagnostic Molecules for the Progesterone-Receptor-Negative Phenotype of Serous Ovarian Tumors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 12214.	4.1	1
228	Testing Whether Cancer Screening Saves Lives. <i>JAMA Internal Medicine</i> , 2023, 183, 1255.	5.1	6
229	Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial. <i>Lancet Oncology</i> , The, 2023, 24, 1018-1028.	10.7	6
230	Construction of an Immunophenoscore-Related Signature for Evaluating Prognosis and Immunotherapy Sensitivity in Ovarian Cancer. <i>ACS Omega</i> , 0, , .	3.5	0
231	Artificial intelligence in ovarian cancer histopathology: a systematic review. <i>Npj Precision Oncology</i> , 2023, 7, .	5.4	5
232	Cell-free DNA approaches for cancer early detection and interception. , 2023, 11, e006013.		7
233	Deceptive shifts in cancer stage distribution. <i>BMJ Evidence-Based Medicine</i> , 0, , bmjebm-2023-112238.	3.5	1
234	Biomarkers and biosensors for early cancer diagnosis, monitoring and prognosis. <i>Pathology Research and Practice</i> , 2023, 250, 154812.	2.3	0
235	Altered expression of the L-arginine/nitric oxide pathway in ovarian cancer: metabolic biomarkers and biological implications. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
236	Advanced stage, high-grade primary tumor ovarian cancer: a multi-omics dissection and biomarker prediction process. <i>Scientific Reports</i> , 2023, 13, .	3.3	2
237	Transcriptome analyses reveal new insights on key determinants of perineural invasion in high-grade serous ovarian cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	3.7	0
238	Diagnostic value of CA125, HE4, and systemic immune-inflammation index in the preoperative investigation of ovarian masses. <i>Medicine (United States)</i> , 2023, 102, e35240.	1.0	1

#	ARTICLE	IF	CITATIONS
239	Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap. <i>Expert Opinion on Therapeutic Targets</i> , 2023, 27, 841-860.	3.4	0
240	General Features of Ovarian Cancer. , 2023, , 9-14.		0
241	Impact of supradiaphragmatic lymphadenectomy on the survival of patients in stage IVB ovarian cancer with thoracic lymph node metastasis. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
242	Early Detection of Ovarian Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 0, , a041337.	6.2	1
243	Serum Free Fatty Acid Changes Caused by High Expression of Stearoyl-CoA Desaturase 1 in Tumor Tissues Are Early Diagnostic Markers for Ovarian Cancer. <i>Cancer Research Communications</i> , 2023, 3, 1840-1852.	1.7	0
244	Reduction-responsive supramolecular hybridized paclitaxel nanoparticles for tumor treatment. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 11, .	4.1	0
245	Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker. <i>Cancer Discovery</i> , 2023, 13, 2532-2547.	9.4	10
246	Evaluating multi-cancer early detection tests: an argument for the outcome of recurrence-updated stage. <i>British Journal of Cancer</i> , 2023, 129, 1209-1211.	6.4	2
248	Prophylactic Salpingo-Oophorectomy and Survival After <i>BRCA1/2</i> Breast Cancer Resection. <i>JAMA Surgery</i> , 0, , .	4.3	0
250	OvaPrint™ A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 5196-5206.	7.0	1
251	A predictive and prognostic model for surgical outcome and prognosis in ovarian cancer computed by clinico-pathological and serological parameters (CA125, HE4, mesothelin). <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, .	2.3	0
252	Pelvic exam in Gynecology and Obstetrics: French Guidelines for Clinical Practice. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2023, 291, 131-140.	1.1	1
253	Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials. <i>Health Technology Assessment</i> , 0, , 1-38.	2.8	0
255	An epigenetic hypothesis for ovarian cancer prevention by oral contraceptive pill use. <i>Clinical Epigenetics</i> , 2023, 15, .	4.1	0
256	There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes. <i>Annals of Oncology</i> , 2024, 35, 138-139.	1.2	1
257	Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial. <i>International Journal of Cancer</i> , 2024, 154, 679-691.	5.1	0
259	Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
260	Current and Emerging Strategies for Tubo-Ovarian Cancer Diagnostics. <i>Diagnostics</i> , 2023, 13, 3331.	2.6	0

#	ARTICLE	IF	CITATIONS
261	Topâ€œDown Proteomics of Human Saliva, Analyzed with Logistic Regression and Machine Learning Methods, Reveal Molecular Signatures of Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 15716.	4.1	0
262	Protocol to evaluate sequential electronic health record-based strategies to increase genetic testing for breast and ovarian cancer risk across diverse patient populations in gynecology practices. <i>Implementation Science</i> , 2023, 18, .	6.9	0
263	Circulating tumor DNA (ctDNA): can it be used as a pan-cancer early detection test?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 0, , 1-13.	6.1	2
264	Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer â€œ An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Gynecologic Oncology</i> , 2023, 179, 123-130.	1.4	1
265	Targeting Ovarian Cancer with Chalcone Derivatives: Cytotoxicity and Apoptosis Induction in HGSOE Cells. <i>Molecules</i> , 2023, 28, 7777.	3.8	0
266	Beyond Sterilization: A Comprehensive Review on the Safety and Efficacy of Opportunistic Salpingectomy as a Preventative Strategy for Ovarian Cancer. <i>Current Oncology</i> , 2023, 30, 10152-10165.	2.2	1
267	Combined Bilateral Salpingo-oophorectomy and Cesarean Delivery in BRCA1/2 Alteration Carriers. <i>Obstetrics and Gynecology</i> , 2023, 142, 1500-1503.	2.4	1
268	Opportunistic Salpingectomy Between 2017 and 2020: A Descriptive Analysis. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2023, , 102278.	0.7	0
269	RNF144B-mediated p21 degradation regulated by HDAC3 contribute to enhancing ovarian cancer growth and metastasis. <i>Tissue and Cell</i> , 2024, 86, 102277.	2.2	0
270	Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation. <i>Cancer Research Communications</i> , 2023, 3, 2420-2429.	1.7	0
271	Ovarian Cancer: From Precursor Lesion Identification to Population-Based Prevention Programs. <i>Current Oncology</i> , 2023, 30, 10179-10194.	2.2	1
272	Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	2
273	Cancers of the Female Genital Tract. , 2023, , 31-45.		0
274	Childhood body fatness and the risk of epithelial ovarian cancer: A population-based case-control study in Montreal, Canada. <i>Preventive Medicine</i> , 2024, 178, 107794.	3.4	0
275	Complications after opportunistic salpingectomy compared with tubal ligation at cesarean section: a retrospective cohort study. <i>Fertility and Sterility</i> , 2024, 121, 531-539.	1.0	1
276	Bioinformatics Analyzes the Mechanisms of Codonopsis Radix in Treating Ovarian Cancer. <i>Pharmacognosy Magazine</i> , 0, , .	0.6	0
277	Contraception as chemoprevention of ovarian cancer in BRCA1 and BRCA2 women. <i>Hormones</i> , 0, , .	1.9	0
278	Habitat Radiomics Based on MRI for Predicting Platinum Resistance in Patients with High-Grade Serous Ovarian Carcinoma: A Multicenterâ€œStudy. <i>Academic Radiology</i> , 2023, , .	2.5	0

#	ARTICLE	IF	CITATIONS
279	Diagnostic Dilemmas in Ovarian Cancer. <i>Indian Journal of Gynecologic Oncology</i> , 2024, 22, .	0.3	0
280	Novel antibody biomarker P85-Ab improved the performance of nasopharyngeal carcinoma screening. <i>Chinese Science Bulletin</i> , 2023, , .	0.7	0
282	Normal Risk Ovarian Screening Study: 21-Year Update. <i>Journal of Clinical Oncology</i> , 2024, 42, 1102-1109.	1.6	0
283	The High Sensitivity of the Multi-Cancer Detection Test ONCOVERYX-F Offers a Promising Platform for Ovarian Cancer Screening. <i>International Journal of Women's Health</i> , 0, Volume 16, 1-7.	2.6	0
284	Early Ovarian Cancer Detection in the Age of Fallopian Tube Precursors. <i>Obstetrics and Gynecology</i> , 2024, 143, e63-e77.	2.4	0
285	Cancer screening: Theory and applications. , 2024, , .		0
286	Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer. <i>British Journal of Cancer</i> , 2024, 130, 861-868.	6.4	0
287	Artificial intelligence-based models enabling accurate diagnosis of ovarian cancer using laboratory tests in China: a multicentre, retrospective cohort study. <i>The Lancet Digital Health</i> , 2024, 6, e176-e186.	12.3	0
288	CT-Based Radiomics and Machine Learning for Differentiating Benign, Borderline, and Early-Stage Malignant Ovarian Tumors. , 2024, 37, 180-195.		0
289	Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies. <i>Journal of Ovarian Research</i> , 2024, 17, .	3.0	0
290	High-Grade Serous Ovarian Cancerâ€™A Risk Factor Puzzle and Screening Fugitive. <i>Biomedicines</i> , 2024, 12, 229.	3.2	0
291	Integrated transcriptome and cell phenotype analysis suggest involvement of PARP1 cleavage, Hippo/Wnt, TGF-Î² and MAPK signaling pathways in ovarian cancer cells response to cannabis and PARP1 inhibitor treatment. <i>Frontiers in Genetics</i> , 0, 15, .	2.3	0
292	Toward ovarian cancer screening with protein biomarkers using dried, self-sampled cervico-vaginal fluid. <i>IScience</i> , 2024, 27, 109001.	4.1	0
293	Unveiling the Promise: A Comprehensive Review of Salpingectomy as a Vanguard for Ovarian Cancer Prevention. <i>Cureus</i> , 2024, , .	0.5	0
294	Clinical performance and utility: A microsimulation model to inform the design of screening trials for a multi-cancer early detection test. <i>Journal of Medical Screening</i> , 0, , .	2.3	0
295	Uterine washings as a novel method for early detection of ovarian cancer: Trials and tribulations. <i>Gynecologic Oncology Reports</i> , 2024, 51, 101330.	0.6	0
296	The National Health Service urgent cancer referral pathway for suspected urological cancers: early economic evaluation of a risk prediction test. <i>International Journal of Technology Assessment in Health Care</i> , 2024, 40, .	0.5	0
297	Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis. <i>Gynecologic Oncology</i> , 2024, 184, 190-197.	1.4	0

#	ARTICLE	IF	CITATIONS
298	Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer. JAMA Network Open, 2024, 7, e2355324.	5.9	0
299	Screening and prevention of ovarian cancer. Medical Journal of Australia, 2024, 220, 264-274.	1.7	0
300	An assessment of survival outcomes among ovarian cancer patients at the National and Referral Hospital in Kenya. Cancer Reports, 2024, 7, .	1.4	0
301	Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer”Genetic Instability and Clinical Implications. Cells, 2024, 13, 345.	4.1	0
302	Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health. Oncotarget, 2024, 15, 134-141.	1.8	0
303	Familial Ovarian Cancer Surveillance, Genetics, and Pathology. , 2023, , 267-284.		0
304	Ovarian Cancer Screening in the General Population. , 2023, , 77-94.		0
305	Bilateral Oophorectomy and All-Cause Mortality in Women With <i>BRCA1</i> and <i>BRCA2</i> Sequence Variations. JAMA Oncology, 2024, 10, 484.	7.1	0
306	Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4. Therapeutic Advances in Medical Oncology, 2024, 16, .	3.2	0
307	A novel interpretable regularized cnn with a modified xlnet transformer for segmenting and classifying the ovarian cancer. Multimedia Tools and Applications, 0, , .	3.9	0
308	Innovation in gynaecological cancer: highlighting global disparities. Lancet Oncology, The, 2024, 25, 425-430.	10.7	0
309	Protocol for identifying metabolite biomarkers in patient uterine fluid for early ovarian cancer detection. STAR Protocols, 2024, 5, 102953.	1.2	0
310	Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer diagnostics. Gynecologic Oncology, 2024, , .	1.4	0
311	Using online search activity for earlier detection of gynaecological malignancy. BMC Public Health, 2024, 24, .	2.9	0
312	Identification of different subtypes of ovarian cancer and construction of prognostic models based on glutamine-metabolism associated genes. Heliyon, 2024, 10, e27358.	3.2	0
313	Glutamine metabolism prognostic index predicts tumour microenvironment characteristics and therapeutic efficacy in ovarian cancer. Journal of Cellular and Molecular Medicine, 2024, 28, .	3.6	0